For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Tafamidis and Tafamidis meglumine represents a true change. These groundbreaking therapies protect the transthyretin protein, halting its harmful build-up and reducing the impact of the illness. People are now seeing improvements in t